semaglutide news 2025 EASD 2025: Pooled analysis highlights CV benefits of in dialysis patients Off-patent semaglutide in 2026: the

The pharmaceutical company Novo Nordisk shared the results of its study in a press release: the medications were shown to reduce the risk of suffering adverse cardiovascular events in people with obesity and overweight

Half-unit syringes add intermediate marks between each unit, allowing measurement to 0.5-unit precision

It belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists , which work by mimicking a naturally occurring hormone that regulates appetite and food intake

That drug may be coming from a red-flagged pharmacy If you go to a med spa for GLP-1 injections, you may want to start asking questions about where those drugs are actually coming from

Without adequate protein intake and strength training, some weight lost during semaglutide therapy can come from muscle rather than fat